Ohcanbohtosat - DeFronzo, Ralph A.
- Čájehuvvo 1 - 20 / 161
- Sirdás čuovvovaš siidui
-
1
-
2
-
3
The EMPA-REG study: What has it told us?: A diabetologist’s perspective Dahkki DeFronzo, Ralph A.
Almmustuhtton 2015Teaksta -
4
COMBINATION THERAPY WITH GLP-1 RECEPTOR AGONIST AND SGLT2 INHIBITOR Dahkki DeFronzo, Ralph A.
Almmustuhtton 2017Teaksta -
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Sodium–Glucose Cotransporter 2 Inhibitors and the Kidney Dahkki DeFronzo, Ralph A., Abdul-Ghani, Muhammad
Almmustuhtton 2021Teaksta -
15
-
16
-
17
Pathogenesis of Insulin Resistance in Skeletal Muscle Dahkki Abdul-Ghani, Muhammad A., DeFronzo, Ralph A.
Almmustuhtton 2010Teaksta -
18
-
19
-
20
Dapagliflozin for the treatment of type 2 diabetes Dahkki Abdul-Ghani, Muhammad A, DeFronzo, Ralph A
Almmustuhtton 2013Teaksta